Phase II/III CRO Benchmarking: Small Biopharma Market (7th Ed.)

This report is created to help CROs optimize operational and marketing strategies to better accommodate small and emerging biopharma customers. A service provider can’t successfully promote its services without understanding its brand awareness and position in the market. The degree of detail provided in this report – straight from small and emerging biopharma customers – on their provider selection process as well as awareness, familiarity, reported use, perceived leadership, and cost perceptions of Phase II/III CROs will support your company’s marketing efforts to reach this segment, while communicating the information most valuable to them.

What you will learn:

Service Provider Selection Process

• Use of preferred provider agreements
• Key CRO selection drivers across three decision-making scenarios
• Use of outside consultants for CRO identification and selection

Service Provider Perceptions and Interactions

• Leadership, familiarity, and reported recent use of Phase II/III CROs
• Service provider preference
• Service provider preference among users of each provider

Service Provider Cost and Value

• Cost perceptions
• Cost experience among users of each provider
• Customer satisfaction with value received

Service Provider Performance and Loyalty

• Aggregated performance scores across 14 core attributes
• Aggregated performance scores across 8 specialized service areas
• Aggregated scores for Overall Satisfaction, Likelihood to Use Again, and Likelihood to Recommend (broken out by CRO size)
• Verbatim explanations for Overall Satisfaction ratings

Included Providers:

All listed providers will have data for awareness, familiarity, reported usage, preference, and cost perceptions in the report.

• Advanced Clinical
• Allucent
• Altasciences
• Caidya
• ClinChoice
• CTI Clinical Trial & Consulting
• DCRI-Duke
• Emerald Clinical Trials (formerly George Clinical)
• Emmes CRO
• Eurofins
• Fortrea
• ICON
• Indero (formerly Innovaderm)
• IQVIA
• Lambda
• Medpace
• Novotech
• Novum
• Ora
• Parexel
• PPD (part of Thermo Fisher)
• Precision for Medicine
• Premier Research
• ProPharma
• ProSciento
• PSI
• QPS
• SGS Health Science
• Syneos Health
• UBC
• Veristat
• Worldwide Clinical Trials
• WuXi Clinical

Respondents were required to pass several screening criteria to qualify and participate in this survey:

• Must work at a pharmaceutical company, biotech company, or medical device company with annual R&D spend less than $100 million
• Must have responsibility in at least one of several relevant areas such as Clinical Operations, Project Management, Executive Management, Medical, Outsourcing/Procurement, or Research and Development Management
• Must have involvement with outsourced Phase II/III trials within past 12 months